GKA

Hua Medicine Announces 2023 Interim Results

Retrieved on: 
Friday, August 25, 2023
IGT, DREAM, National Healthcare Security Administration, Rat, Type 2 diabetes, Diabetes, Obesity, Progress, Hong Kong Exchanges and Clearing, Hospital, Patient, NGT, Fructose, American Diabetes Association, ADA, Disease, Pharmacy, Drug discovery, DSM-IV codes, Pancreas, Research, Homeostasis, Kidney, PPG, FKI, Liver, Growth, IND, Fatty liver disease, Endocrinology, DPP-4, Stroke, Chinese University of Hong Kong, MAH, Type 2, Metformin, CUHK, IVD, STA, DKD, Glucokinase, Probability, Metabolism, Liver disease, GK, Nature Communications, SEED, Trial of the century, TIR, Plasma protein binding, GKA, National Healthcare, Physician, AI, Bank, NRDL, Medicine, Congenital hyperinsulinism, Medical device, Pharmaceutical industry, Cryptocurrency, Bayer, T2D

Hua Medicine (the "Company", HKEx: 2552) today announces the unaudited consolidated results of the Company and its subsidiaries for the six months ended June 30, 2023 (the "Reporting Period").

Key Points: 
  • Hua Medicine (the "Company", HKEx: 2552) today announces the unaudited consolidated results of the Company and its subsidiaries for the six months ended June 30, 2023 (the "Reporting Period").
  • Dr. Li Chen, the founder and CEO of Hua Medicine, said, "the first half of 2023 was a critical stage for Hua Medicine to begin commercialization.
  • The revenue of Hua Medicine for the first half of 2023 was RMB70.3 million, which was an increase of approximately 299.6% comparing to the second half of 2022.
  • This article contains the statements regarding the future expectations, plans and prospects for Hua Medicine and the investigational product.

Intergalactic Social Media Launches the Galactix Zone Project

Retrieved on: 
Thursday, November 24, 2022
Social media, FITS, NFT, Corruption, DNA, Life, Trust, GKA, Non-fungible token, RISK, Silver, Ram, GEO, Pheas River, Ecosystem, KYC, Cryptocurrency, Renewable energy, Audit

RICHMOND, Va., Nov. 24, 2022 (GLOBE NEWSWIRE) -- Intergalactic Social Media, a collective of crypto advisors and developers spearheaded by founders John Nguyen and Phea Ram, has officially launched its first NFT project, the Galactix Zone .

Key Points: 
  • RICHMOND, Va., Nov. 24, 2022 (GLOBE NEWSWIRE) -- Intergalactic Social Media, a collective of crypto advisors and developers spearheaded by founders John Nguyen and Phea Ram, has officially launched its first NFT project, the Galactix Zone .
  • Galactix Zone, also known as Galactix Zone Kalpa Avian or GKA, will set itself apart through innovations made possible by dNFT technology.
  • Through these audits and verification checks, the Intergalactic Social Media team hopes to instill a strong sense of trust and transparency within the greater Galactix Zone community.
  • Intergalactic Social Media, LLC is the developer of the Galactix Zone project.

Extreme Tech Challenge and ACTAI Global Join Forces to Accelerate Web3 Global Conversations and Adoption Organizations to host inaugural Neckerverse Summit

Retrieved on: 
Monday, August 1, 2022
Consensus, CFO, GLOBE, Aviation, Jet card, Foundation, Sustainable Development Goals, United Nations, Web browser, CEO, Outline, Entrepreneurship, Compliance, DAO, University, Risk management, Travel, Leadership, Great House, Technology, Government, Blockchain, ExtremeTech, Consensus decision-making, Great, Burj Al Arab, YOU, XTC, Program, Porsche, Science, NFT, GKA, Video game, Public relations, Cryptocurrency, Tourism, Metaverse, Athlete, BVI

Web3 is opening the door to a new, more collaborative era, said Bill Tai, founder of ACTAI Global and co-founder of Extreme Tech Challenge.

Key Points: 
  • Web3 is opening the door to a new, more collaborative era, said Bill Tai, founder of ACTAI Global and co-founder of Extreme Tech Challenge.
  • The Neckerverse summit will also host a Web3 showcase featuring 3 startup winners of the "Web3 Pitch Fest", a joint effort of the Extreme Tech Challenge and Coindesk.
  • Extreme Tech Challenge is a 501(c)(3) public benefit corporation whose mission is to empower start-ups creating new tech innovations to address global challenges.
  • Maria Serafica Event Director, Neckerverse; CFO, ACTAI Global: [email protected]
    Victoria Slivkoff Executive Managing Director, Extreme Tech Challenge: [email protected]
    Brad Cohen Executive Vice President of Sales, TapJets: [email protected]
    For the original news story, please visit: https://prdistribution.com/news/extreme-tech-challenge-and-actai-global-...

Hua Medicine Announces Dorzagliatin can Restore Glucose Sensitivity and Early Phase Insulin Secretion in T2DM and GCK-MODY Patients at ADA 2022

Retrieved on: 
Tuesday, June 7, 2022
DREAM, Woman, National Medical Products Administration, GK, Company, FPG, GKA, Observation, DAWN, Research, Jak Airport, ADA, CEO, Education, Disease, World Diabetes Day, Type 2 diabetes, Insulin resistance, Patient, Glycated hemoglobin, Insulin, Metformin, Trial of the century, Chinese, Glucokinase, Type 2, Association, American Diabetes Association, Department, Public health, Hospital, NDA, Blood, Homeostasis, Drug development, Chinese University of Hong Kong, Attention, Glucose clamp technique, China-Japan Friendship Hospital, WIN, SEED, Pharmaceutical industry, Epidemiology, Diabetes, T2D

A post-hoc analysis that involved two Phase III clinical trials of dorzagliatin indicated that dorzagliatin can significantly improve early phase insulin secretion and glucose sensitivity of patients of Type 2 diabetes (T2D).

Key Points: 
  • A post-hoc analysis that involved two Phase III clinical trials of dorzagliatin indicated that dorzagliatin can significantly improve early phase insulin secretion and glucose sensitivity of patients of Type 2 diabetes (T2D).
  • Another clinical study called SENSITIZE also provided clinical scientific data of dorzagliatin in improving insulin secretion and glucose sensitivity.
  • The study results, using glucose clamp technique, showed that dorzagliatin can significantly improve second phase insulin secretion and glucose sensitivity in GCK-MODY patients and can significantly improve basal insulin secretion rates in patients with recent onset T2D.
  • Targeting the glucose sensor glucokinase, dorzagliatin, a novel oral diabetes drug restoring glucose sensitivity in T2D patients, has completed SEED and DAWN registration trials, and filed NDA in China.

CUHK Professor Elaine Chow Receives "2022 Women's Interprofessional Network of the American Diabetes Association Abstract Award" for Outstanding Research and Care in Diabetes

Retrieved on: 
Sunday, June 5, 2022
Woman, GKA, ADA, List of universities in China, World Diabetes Day, Patient, Faculty, Trial of the century, T2D, Li Ka Shing Faculty of Medicine, Chinese, Public health, Chinese University of Hong Kong, WIN, Education, Pharmaceutical industry, Epidemiology, Medicine

The WIN ADA abstract award category of Clinical Diabetes, Epidemiology, and Diabetes Complications is an important part of WIN ADA awards, voted by WIN ADA Advisory Group, consisting of expert clinicians, scientists, educators, public health practitioners, and other diabetes professionals.

Key Points: 
  • The WIN ADA abstract award category of Clinical Diabetes, Epidemiology, and Diabetes Complications is an important part of WIN ADA awards, voted by WIN ADA Advisory Group, consisting of expert clinicians, scientists, educators, public health practitioners, and other diabetes professionals.
  • It honours women who have made significant contributions to the diabetes research, clinical care, public health, education, and related areas worldwide.
  • The award was presented to Professor Elaine on June 3, 2022.
  • Professor Elaine will present a clinical study called SENSITIZE, which explored the effects of dorzagliatin, the global first-in-class drug, glucokinase activator (GKA) at the ADA Annual Scientific Sessions.

vTv Therapeutics Announces Publication in Diabetes Obesity and Metabolism of Complete Results for the Mechanistic Study Assessing Effects of TTP399 on Ketones during Acute Insulin Withdrawal in Patients with Type 1 Diabetes

Retrieved on: 
Saturday, June 4, 2022
People, Ketoacidosis, Cystic fibrosis, Breakthrough therapy, Diabetic ketoacidosis, GKA, DKA, Ketosis, Annual report, JDRF, IWT, Diabetes, Obesity and Metabolism, Acidosis, American Diabetes Association, Metabolic acidosis, Pancreatic cancer, Nasdaq, Kidney, Investment, Chronic obstructive pulmonary disease, Therapy, FDA, Hypoglycemia, GLOBE, Patient, Insulin, Risk, VTV, Diabetes, Review, Metabolism, SEC, Ketone, Food, Safety, Terminology, Pharmaceutical industry, Medical device, T1D, Research

This Phase 1, mechanistic study evaluated the effects of the GKA TTP399 on ketoacidosis risk in individuals with T1D on insulin pump therapy.

Key Points: 
  • This Phase 1, mechanistic study evaluated the effects of the GKA TTP399 on ketoacidosis risk in individuals with T1D on insulin pump therapy.
  • No subject treated with TTP399 met the prespecified definition of DKA while 42% of placebo-treated subjects met this criterion.
  • Together, these data suggest that TTP399 does not increase, and may decrease, the risk of diabetic ketoacidosis (DKA) in subjects with T1D.
  • This past October, vTv announced results of a mechanistic study of TTP399 in patients with type 1 diabetes demonstrating no increased risk of ketoacidosis.

Hua Medicine Published Two Peer-Reviewed Papers in Nature Medicine, an International Top Medical Journal, on the Results of the Phase III Research of Dorzagliatin, a First-In-Class Investigational Diabetes Drug of Hua Medicine

Retrieved on: 
Friday, May 13, 2022
Diabetes, JAMA, Nature Reviews Drug Discovery, Company, Glucose, National Medical Products Administration, BMJ, Blood, Journal, Drug discovery, American Diabetes Association, GSIS, Pancreas, Medical college, Patient, Hypoglycemia, Homeostasis, Phase, NEJM, DAWN, Liver, Medical journal, Nanjing University, GKA, The New England Journal of Medicine, Trial of the century, Research, FPG, ADA, GK, NMPA, Safety, Insulin, Glucagon, NDA, American Medical Association, The Lancet, Metformin, Glucokinase, Insulin resistance, SEED, Medical Center, Hong Kong Stock Exchange, Inborn errors of metabolism, Glycated hemoglobin, Nature Medicine, Pharmaceutical industry, Medical device, Endocrinology, T2D, Lancet

The results of the Phase III trial published by Nature Medicine are the clinical validation of this innovative concept.

Key Points: 
  • The results of the Phase III trial published by Nature Medicine are the clinical validation of this innovative concept.
  • Before, the results of the Phase II clinical trial of dorzagliatin were published in the advanced medical journal The Lancet Diabetes and Endocrinology.
  • These two newly published papers present the Phase III results of the SEED study and the DAWN study of dorzagliatin, respectively.
  • Hua Medicine is an innovative drug development company in China focused on developing novel therapies for patients worldwide with unmet medical needs.

Hua Medicine Announces 2021 Annual Results

Retrieved on: 
Thursday, March 17, 2022
DREAM, People, Trial of the century, Solution, National Medical Products Administration, Technology, DAWN, Conference, LSE Alternative Investment Conference, NMPA, Big data, CEO, Diabetes, New Drug Application, Type 2 diabetes, SEED, GKA, NDA, Homeostasis, New Silk Road Initiative, Conditional sentence, American Diabetes Association, Republic, Metformin, Type 2, 52 Weeks Make A Year, Social Problems, Artificial intelligence, Research, Drug development, Marketing, Patient, Health, Glucokinase, Type 1, Wuxi, Disease, Glycated hemoglobin, Insulin, Company, Belt, Pharmaceutical industry, Medical device, T2D, Sitagliptin, Bayer

SHANGHAI, CHINA, Mar 17, 2022 - (ACN Newswire) - Hua Medicine (the "Company", Stock Code: 2552.HK) today announces the audited annual results of the Company and its subsidiaries for the year ended December 31, 2021 (the "Reporting Period").

Key Points: 
  • SHANGHAI, CHINA, Mar 17, 2022 - (ACN Newswire) - Hua Medicine (the "Company", Stock Code: 2552.HK) today announces the audited annual results of the Company and its subsidiaries for the year ended December 31, 2021 (the "Reporting Period").
  • Dr. Li CHEN, the founder, CEO and Chief Scientific Officer of Hua Medicine, said, "2021 was a breakthrough year for Hua Medicine.
  • Hua Medicine is an innovative drug development company in China focused on developing novel therapies for patients worldwide with unmet medical needs.
  • Hua Medicine teams up with global high caliber people and integrates global resources to explore breakthrough technologies and products, and accelerate global innovation in diabetes care.

Gerod W. King is recognized by Continental Who's Who

Retrieved on: 
Wednesday, December 1, 2021
International Coaching Federation, Associate, Justice minister, Army Reserve, Private practice, DEI, Continental, Bachelor, Business, ACC, Public relations, Federation, View, Grandparent, Trust (social science), Lead, Coaching, GKA, North Carolina Central University, North Carolina, ICF, Seton Hall University, Multimedia, Public administration, Human resources, Tutoring, Medicine

WEDDINGTON, N.C., Dec. 1, 2021 /PRNewswire/ --Gerod W. King is being recognized by Continental Who's Who as a Trusted Coach/Trainer for his dedication to the Business Coaching industry and in recognition of his exceptional work at his private practice, Gerod King and Associates LLC (GKA).

Key Points: 
  • WEDDINGTON, N.C., Dec. 1, 2021 /PRNewswire/ --Gerod W. King is being recognized by Continental Who's Who as a Trusted Coach/Trainer for his dedication to the Business Coaching industry and in recognition of his exceptional work at his private practice, Gerod King and Associates LLC (GKA).
  • To begin his career, Mr. King attended North Carolina Central University, graduating with a Bachelor's degree in Public Administration.
  • Mr. King served in the U.S. Army Reserve for 20 years, retiring at Fort Knox, KY in 2007.
  • He is passionate about helping others change how they think, lead, and live through his private practice, Gerod King and Associates LLC.

Hua and Sinopharm Announced Supply Chain Strategic Cooperation

Retrieved on: 
Wednesday, September 15, 2021
Insulin, Metformin, NDA, National Medical Products Administration, CEO, Efficiency, Sinopharm Group, Marketing, Diabetes, Ecosystem, Patient, Shanghai Stock Exchange, Company, Type 2, Medicine, GKA, Bayer, T2DM, Homeostasis, Disease, New Drug Application, HK, T2D, Glucokinase, City, Stock exchange, NMPA, News, Type 2 diabetes, Partnership, Hong Kong Stock Exchange, Pharmaceutical industry

SHANGHAI, CHINA, Sept 15, 2021 - (ACN Newswire) - On September 13, 2021, Hua Medicine (Shanghai) Ltd. (the "Hua Medicine", Stock Code: 2552.HK) has signed a supply chain strategic cooperation agreement with Sinopharm Group Co., Ltd. (the "Sinopharm", Stock Code: 1099).

Key Points: 
  • SHANGHAI, CHINA, Sept 15, 2021 - (ACN Newswire) - On September 13, 2021, Hua Medicine (Shanghai) Ltd. (the "Hua Medicine", Stock Code: 2552.HK) has signed a supply chain strategic cooperation agreement with Sinopharm Group Co., Ltd. (the "Sinopharm", Stock Code: 1099).
  • Hua Medicine will rely on Sinopharm's nation-wide drug distribution network to carry out in-depth cooperation in supply chain management.
  • "We are very glad to witness the strategic cooperation between Sinopharm and Hua Medicine, opening a new chapter on our cooperation.
  • In recent years, Sinopharm continue to innovate and build up the new ecosystem of the smart pharmaceutical and supply chain, improving the efficiency of supply chain.